AbbVie closes $200M Nimble Therapeutics acquisition

by
Contributor since / Followers
21 hours ago
M&A word made with building blocks

SB

  • AbbVie (NYSE:ABBV) has completed its $200M acquisition of Nimble Therapeutics.
  • Nimble’s lead asset is an oral peptide IL23R inhibitor in preclinical development for psoriasis.
  • Nimble was spun out of Roche (OTCQX:RHHBY) in 2019.
Tags:

Leave a Reply

Your email address will not be published. Required fields are marked *